Strumento inattivo

Altre lingue GTx, Inc. Nasdaq

Azioni

US40052B1089

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Oncternal Therapeutics : Corporate Presentation, May 2024	02:16
Oncternal Therapeutics: Q1 Earnings Snapshot	09/05
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results	09/05
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results	02/05
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01/05
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer	15/03
Oncternal Therapeutics: Q4 Earnings Snapshot	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	07/03
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results	29/02
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01/02
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science	01/02
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics Announces Reverse Stock Split	04/01
Oncternal Therapeutics Reports Inducement Award under Nasdaq Listing Rule 5635(4)	03/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue GTx, Inc. Nasdaq

Azioni

US40052B1089

Altre lingue

Filtri